Taking Tegretol does not cause a decrease in platelets. Tegretol inhibits platelet aggregation and reduces platelet function, but not platelet count. Tegretol and metabolites, can reversibly interact with platelet P2Y12ADP receptor, block signaling, platelet activation, thus providing anticoagulation. Tegretol is indicated in patients with acute coronary syndromes, including unstable angina, myocardial infarction, and post-PCI, to reduce the incidence of thrombotic cardiovascular events. Adverse reactions of Tegretol are mainly hemorrhagic disorders, such as cerebral hemorrhage, gastrointestinal hemorrhage, skin hemorrhage, subcutaneous hemorrhage, contusion, hematoma, hematuria, urethral hemorrhage, bleeding at the site of vascular puncture and hematoma, and bleeding at the site of injection; in addition, hyperuricemia and respiratory distress are also possible adverse reactions. Taking Tegretol should be used under medical supervision, coagulation function should be monitored during treatment, and bleeding tendency or active bleeding should be detected, go to the hospital in time.